8-K: Medifast Reports Q1 2026 Results, Net Loss of $2.1M

Medifast announced its first quarter 2026 financial results, reporting a revenue of $76.0 million and a net loss of $2.1 million, or $0.19 per diluted share.

Summary

• Medifast reported first quarter 2026 revenue of $76.0 million, a decrease of 34.3% compared to $115.7 million in the first quarter of 2025.
• The company experienced a net loss of $2.1 million, or $0.19 per diluted share, compared to a net loss of $0.8 million, or $0.07 per diluted share, in the prior year period.
• Active earning coaches decreased by 44.9% to 14,000 compared to 25,400 in Q1 2025, primarily due to challenges in client acquisition and the impact of GLP-1 medications.
• Average revenue per active earning coach increased by 19.2% to $5,432, driven by a focus on productive coaches.
• Gross profit decreased by 38.6% to $51.8 million, with gross profit margin declining to 68.1% from 72.8%.
• Selling, general, and administrative (SG&A) expenses decreased by 35.6% to $55.1 million, partly due to lower coach compensation and a one-time gain on the sale of a distribution center building.
• The company ended the quarter with $168.9 million in cash, cash equivalents, and investment securities and no debt.
• Medifast anticipates continued decline in active earning coaches throughout 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant revenue decline, widening net loss, and a shrinking coach network, despite some operational efficiencies and a strong balance sheet.

Positives

• Second consecutive quarter of year-over-year coach productivity growth.
• Strong coach leadership advancement and high field engagement.
• Average revenue per active earning coach increased by 19.2% to $5,432.
• A one-time gain of $2.2 million on the sale of the Maryland Distribution Center building and land.
• SG&A expenses as a percentage of revenue decreased by 150 basis points year-over-year to 72.4%.
• Strong balance sheet with $168.9 million in cash, cash equivalents, and investment securities and no debt.
• Working capital increased to $160.4 million from $158.7 million.

Negatives

• Revenue decreased 34.3% to $76.0 million compared to $115.7 million in Q1 2025.
• Net loss increased to $2.1 million ($0.19 per share) from $0.8 million ($0.07 per share) in Q1 2025.
• Total active earning coaches decreased 44.9% to 14,000.
• Gross profit margin decreased to 68.1% from 72.8%.
• Loss from operations increased to $3.3 million from $1.3 million in the prior year period.
• Expects the number of active earning coaches to continue to decline in 2026.

Risks

• Continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid adoption of GLP-1 medications for weight loss.
• Expectation that the number of active earning coaches will continue to decline in 2026.
• Loss of leverage on fixed costs due to lower sales volume impacting gross profit margin.
• Potential for increased litigation.
• Competitors' use of artificial intelligence to make their offers more competitive.
• Disruptions in Medifast's supply chain.
• Product liability claims.
• The impact of existing and future laws and regulations on Medifast's business.

Future Outlook

The company expects second quarter 2026 revenue to be between $60 million and $80 million, with a loss per share ranging from $0.50 to $1.00. For the full year 2026, revenue is projected to be between $270 million and $300 million, with a loss per share expected to range from $1.55 to $2.75. Medifast anticipates the number of active earning coaches to continue to decline in 2026.

Management Comments

• "We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership advancement, and high field engagement. These are metrics that have historically been leading indicators of future growth."
• "Backed by our differentiated science, coach-led model, and a disciplined approach to managing costs, we believe we are well positioned to drive improved performance through the remainder of 2026 and a return to sustainable, long-term growth in the years ahead."

Industry Context

StockSavvy.ai notes that Medifast's results reflect significant headwinds in the weight loss industry, particularly the impact of GLP-1 medications. The decline in active coaches and revenue aligns with broader industry shifts towards pharmaceutical weight loss solutions, challenging traditional lifestyle and coaching-based models. The company's strategic pivot to 'metabolic health' and emphasis on coach productivity are attempts to adapt to this evolving landscape.

Comparison to Industry Standards

• The decline in revenue and active coaches for Medifast is steeper than some competitors in the broader wellness sector, but aligns with companies directly impacted by the rapid rise of GLP-1 drugs.
• Competitors focusing on pharmaceutical weight loss solutions, such as those partnering with or developing GLP-1 based programs, are experiencing different growth trajectories.
• Companies with diversified revenue streams or those not solely reliant on direct-to-consumer coaching models may be better insulated from these specific pressures.

Stakeholder Impact

• Shareholders: Negative impact due to widening net loss and projected continued decline in active coaches, potentially affecting future profitability and stock performance.
• Employees: Potential impact from cost management and realignment of the employee base.
• Coaches: Impacted by the decline in active earning coaches and the company's focus on productive coaches.
• Customers: May experience changes in service delivery or product availability due to shifts in the coach network and business strategy.

Next Steps

• Continue executing the metabolic health strategy.
• Drive improved performance through the remainder of 2026.
• Focus on a return to sustainable, long-term growth.
• Manage costs with a disciplined approach.

Key Dates

Recommendation

While the results are significantly worse than the prior year, the company maintains a strong balance sheet with substantial cash and no debt. Management's focus on coach productivity and metabolic health strategy, coupled with a projected revenue range for Q2 and full-year 2026, suggests a potential stabilization or recovery path. However, the continued expected decline in active coaches and the widening net loss warrant a cautious 'hold' until clearer signs of sustainable growth emerge.

Keywords

Medifast, Q1 2026 Earnings, Metabolic Health, Weight Loss, Coach Network, Revenue Decline, Net Loss, GLP-1 Medications